Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol

MarketBeat

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe

MarketBeat

How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Igor Taldenko: "A Website Outage Today Is an Event That Affects People's Lives"

An engineer with over 12 years of experience working with high-load systems explains why a website outage is no longer just a bug — it's an event capable of derailing transactions, delaying payments, and even impacting people's health — and how to build architecture that minimizes these risks.

inkl

3 Dividend Stocks Yielding Above 5% to Scoop Up Now

These three dividend stocks combine strong yields with resilient businesses.

Barchart

False claims link hantavirus to COVID vaccines

Social media users are claiming that hantavirus was listed as a side effect of the COVID-19 vaccine, but that's a misreading of the facts.

AAP

Lyme disease cases in England rise by more than 20% in a year

Scientists developing vaccines and anti-tick treatments amid growing concern over spread of disease

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Debunked Bill Gates tick theory resurfaces through MAHA social media claims

IN FULL

The Independent UK

MAHA’s latest conspiracy? Blaming Bill Gates for spike in tick bites

The number of tick-related visits to emergency rooms has hit the highest level in the U.S. in nearly a decade

The Independent UK

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

MarketBeat

Valneva Q1 Earnings Call Highlights

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

MarketBeat

Arvinas Q1 Earnings Call Highlights

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

MarketBeat

White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years

The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.

International Business Times

Stock Index Futures Climb as U.S.-Iran Ceasefire Holds, JOLTs Report and Earnings in Focus

June S&P 500 E-Mini futures (ESM26) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.47% this morning, supported by lower oil prices as the ceasefire in the Middle East appeared to be holding.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Bullish on Pfizer Stock?

Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Reason

The COVID Reckoning Doesn't Go Far Enough

Real medical freedom will require something greater than replacing the public health establishment: ending the FDA's monopoly.

The Guardian - US

Will RFK Jr’s podcast actually address Americans’ public health concerns?

Secretary Kennedy Podcast so far seems designed to promote Trump administration talking points over any specific public health message

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Earnings Preview: What to Expect From Pfizer’s Report

Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.

The Times of India

Elon Musk reveals he ‘felt like he was dying’ after a COVID vaccine shot; says the virus was just a bad cold

Tech mogul Elon Musk sparked global vaccine debate by sharing his severe reaction to a COVID-19 vaccine dose, contrasting it with a mild virus infection. His remarks followed testimony by a former Pfizer toxicologist raising concerns about vaccine safety. Health authorities, however, continue to affirm the vaccines' safety and efficacy…

Fortune

Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change

Pfizer CEO Albert Bourla warns U.S. and European universities are falling behind as Chinese institutions surge ahead in research output: “We need to become better.”

The Mary Sue

He knows the pain of Lyme disease better than anyone, but RFK Jr. is about to make a decision that has health experts terrified

Here’s some big news in the fight against Lyme disease: Pfizer just announced its plan to file for regulatory approval of a new Lyme disease vaccine. If it gets the green light, this would be the first vaccine for the tick-borne illness available in over two decades. This new development,…

International Business Times

Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.

MarketBeat

5 High-Yield Stocks to Shield Your Portfolio From the Storm

With the S&P 500 breaking below its 200-day SMA, high-yield dividend stocks are increasingly worth considering as a source of income and portfolio protection.

Euronews

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.